Plant Name: Oocystis polymorpha
Taxonomic Information:
Plant ID: NPO5657
Plant Latin Name: Oocystis polymorpha
Taxonomy Genus: Oocystis
Taxonomy Family: Oocystaceae
Plant External Links:
NCBI TaxonomyDB:
1461600
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Oxidoreductase | HMGCR | HMG-CoA reductase | P04035 | CHEMBL402 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.287E-11 | 4.203E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.841E-10 | 2.788E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.997E-09 | 8.696E-06 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.210E-08 | 6.407E-05 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.942E-08 | 6.407E-05 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.731E-08 | 6.407E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.714E-08 | 9.747E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.823E-07 | 5.528E-04 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.240E-06 | 1.350E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, HMGCR |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.406E-06 | 1.457E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, HMGCR |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.250E-06 | 2.227E-03 | CYP1A1, CYP1A2 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 2.682E-06 | 2.336E-03 | CNR2, CYP1A1, CYP1B1, HMGCR |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 5.603E-06 | 3.697E-03 | CYP19A1, CYP1B1, HMGCR |
| BP | GO:0009987; cellular process | GO:0071280; cellular response to copper ion | 6.262E-06 | 4.011E-03 | CYP1A1, CYP1A2 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 4.614E-03 | 5.658E-01 | CYP1A1, CYP1A2, CYP1B1, HMGCR |
| CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 2.216E-02 | 1.000E+00 | CNR2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 9.508E-10 | 1.426E-08 | CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.476E-07 | 1.107E-06 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.925E-07 | 1.462E-06 | CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.258E-07 | 3.472E-06 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.317E-06 | 3.950E-06 | CYP1A2, CYP1A1, CYP1B1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.988E-04 | 4.259E-04 | CYP1A2, CYP1A1, HMGCR, CYP19A1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.547E-04 | 3.868E-04 | CYP1A2, CYP1A1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 8.670E-03 | 1.300E-02 | CYP1A2 |
| 09100 Metabolism | 09109 Metabolism of terpenoids and polyketides | hsa00900 | Terpenoid backbone biosynthesis | 6.583E-03 | 1.097E-02 | HMGCR |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.499E-03 | 2.811E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
